In the current investigation, the treatment of rats with STZ led to a notable reduction in pancreatic β-cells, hence causing an increase in glucose levels that subsequently triggered the release of insulin and the development of insulin resistance, both of these are prominent characteristics of T2DM [53]. This evidence concerns the gene INS and type 2 diabetes mellitus.